<SEC-DOCUMENT>0001193125-18-249185.txt : 20180815
<SEC-HEADER>0001193125-18-249185.hdr.sgml : 20180815
<ACCEPTANCE-DATETIME>20180815081500
ACCESSION NUMBER:		0001193125-18-249185
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20180814
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180815
DATE AS OF CHANGE:		20180815

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			resTORbio, Inc.
		CENTRAL INDEX KEY:			0001720580
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				813305277
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38359
		FILM NUMBER:		181019775

	BUSINESS ADDRESS:	
		STREET 1:		500 BOYLSTON STREET
		STREET 2:		12TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
		BUSINESS PHONE:		617-482-2333

	MAIL ADDRESS:	
		STREET 1:		500 BOYLSTON STREET
		STREET 2:		12TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d583892d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): August&nbsp;14, 2018 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>RESTORBIO, INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact
name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-38359</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">81-3305277</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>500 Boylston Street, 12th Floor </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Boston, MA 02116 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address
of principal executive offices, including zip code) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(857) <FONT STYLE="white-space:nowrap">315-5521</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former
Name or Former Address, if Changed Since Last Report) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the <FONT STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting material pursuant to <FONT STYLE="white-space:nowrap">Rule&nbsp;14a-12</FONT> under the Exchange Act
(17 CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to <FONT
STYLE="white-space:nowrap">Rule&nbsp;14d-2(b)&nbsp;under</FONT> the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to <FONT
STYLE="white-space:nowrap">Rule&nbsp;13e-4(c)&nbsp;under</FONT> the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&nbsp;230.405 of this
chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;&nbsp;240.12b-2</FONT> of this chapter). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp;&#9746; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange
Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;5.02.&nbsp;Election of Directors. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;14, 2018, resTORbio, Inc. (the &#147;Company&#148;) appointed Jeffrey Chodakewitz, M.D. to its board of directors (the &#147;Board&#148;),
effective immediately. Dr.&nbsp;Chodakewitz was appointed as a Class&nbsp;III director and will serve until the Company&#146;s annual meeting of stockholders in 2021 or until his successor is duly elected and qualified. The Company believes that
Dr.&nbsp;Chodakewitz is qualified to serve as a director based on his substantial experience in leading pharmaceutical companies in the industry in which the Company operates. In addition, Dr.&nbsp;Chodakewitz was appointed to serve on the
compensation committee and nominating and corporate governance committee of the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a <FONT STYLE="white-space:nowrap">non-employee</FONT>
director, Dr.&nbsp;Chodakewitz will receive cash and equity compensation pursuant to the Company&#146;s <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation program. There are no arrangements or understandings between
Dr.&nbsp;Chodakewitz and any other person pursuant to which Dr.&nbsp;Chodakewitz was elected as a director, and there are no transactions between Dr.&nbsp;Chodakewitz and the Company that would require disclosure under Item 404(a) of Regulation <FONT
STYLE="white-space:nowrap">S-K.</FONT> In addition, the Company has entered into an indemnification agreement with Dr.&nbsp;Chodakewitz in connection with his appointment to the Board which is in substantially the same form as that entered into with
the other directors of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with Dr.&nbsp;Chodakewitz&#146;s appointment to the Board, the Company issued a press release on
August&nbsp;15, 2018 titled &#147;resTORbio Appoints Jeffrey Chodakewitz, M.D. to its Board of Directors&#148;, a copy of which is filed herewith as Exhibit 99.1 and is incorporated herein by reference. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01. Financial Statements and Exhibits. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d)&nbsp;Exhibits </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;No.&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d583892dex991.htm">Press release, dated August&nbsp;15, 2018. </A></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;* </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">resTORbio, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: August&nbsp;15, 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Chen Schor</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chen Schor</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">President and Chief Executive Officer</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d583892dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g583892g0813160056009.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>resTORbio Appoints Jeffrey Chodakewitz, M.D., to its Board of Directors </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&#150; Brings extensive experience in clinical and pipeline development to resTORbio&#146;s Board &#150; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>BOSTON, August</B><B></B><B>&nbsp;15, 2018 &#150; </B>resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company focused on helping people
live healthier longer through the development and commercialization of novel therapeutics for the treatment of aging-related diseases, today announced the appointment of Jeffrey Chodakewitz, M.D., to its Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Jeffrey&#146;s extensive experience with clinical and pipeline development, including the fields of respiratory and infectious diseases, makes him a
highly valuable addition to our Board of Directors,&#148; said Chen Schor, President and CEO of resTORbio. &#147;We are delighted to welcome Jeffrey and look forward to his contributions as we progress RTB101 into pivotal trials to reduce the
incidence of respiratory tract infections (RTIs) and initiate additional studies to examine the benefits of TORC1 inhibition in other aging-related diseases.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Chodakewitz has decades of experience holding leadership positions in world class drug development organizations. He currently serves as Executive
Vice President, Clinical Medicine and External Innovation, at Vertex Pharmaceuticals. Until April 2018, Dr.&nbsp;Chodakewitz held the roles of Chief Medical Officer and Executive Vice President, Global Medicines Development and Medical Affairs, at
Vertex and was a member of the Vertex Executive Committee. Prior to joining Vertex in 2014, he spent over 20 years at Merck&nbsp;&amp; Co., where he served in a number of positions including Head of Infectious Diseases and Vaccines Global
Development, Senior Vice President of Global Scientific Strategy (Infectious Disease, Respiratory&nbsp;&amp; Immunology) and Senior Vice President of Late Stage Development. Prior to Merck, he served in academic positions at Yale University School
of Medicine and New York University&#146;s Bellevue Medical Center. Dr.&nbsp;Chodakewitz is a Diplomate of the National Board of Medical Examiners and the American Board of Internal Medicine (both Internal Medicine and Infectious Disease). He holds
a B.S in Biochemistry <I>cum laude</I> from Yale University and an M.D. from the Yale University School of Medicine. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;I am thrilled to join
resTORbio&#146;s Board as the Company progresses RTB101 into late-stage clinical development and gains additional insights on the potential benefits of TORC1 inhibition in other indications,&#148; said Dr.&nbsp;Chodakewitz. &#147;I look forward to
working with the team to further advance our leadership in TORC1 inhibition and the treatment of aging-related diseases.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About resTORbio
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">resTORbio, Inc. is a clinical stage biopharmaceutical company targeting TORC1 and other biological pathways that regulate aging to develop innovative
medicines with the potential to extend healthy lifespan. resTORbio&#146;s lead program is selectively targeting TORC1, an evolutionarily conserved pathway that contributes to the decline in function of multiple organ systems, including the immune,
cardiovascular and central nervous systems. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward Looking Statements: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws. Investors are
cautioned that statements in this press release which are not strictly historical statements, including, without limitation, express or implied statements or guidance regarding our plans to develop and commercialize RTB101, including the
</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g583892g0813160056009.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
therapeutic potential and clinical benefits thereof, the potential benefits of TORC1 inhibition on aging-related diseases, and our planned clinical trials for RTB101, constitute forward-looking
statements identified by words like &#147;believe,&#148; &#147;expect,&#148; &#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;seek,&#148; &#147;anticipate,&#148; or &#147;could&#148; and similar expressions. Such forward-looking
statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: the delay of any planned clinical trials and/or
development of RTB101; our ability to successfully demonstrate the efficacy and safety of our lead product candidate; the clinical results for our lead product candidate which may not support further development of additional indications; and
obtaining, maintaining and protecting our intellectual property; as well as those risks more fully discussed in the section entitled &#147;Risk Factors&#148; in the Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed by
resTORbio, Inc. with the Securities and Exchange Commission, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the Securities and Exchange Commission. In addition, any
forward-looking statements represent our views only as of today and should not be relied upon as representing its views as of any subsequent date. resTORbio explicitly disclaims any obligation to update any forward-looking statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor and Media Contact: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jennifer Robinson </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">resTORbio, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">857-772-7029</FONT></FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">jrobinson@restorbio.com </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g583892g0813160056009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g583892g0813160056009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !! /4# 2(  A$! Q$!_\0
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M=2NKB-K;9+*SKESG!/TKG-4TNXTB]^RW10R;0WR'(P:]@TZ]34=.M[R,869
MP'I7F_CO_D9C_P!<4_K7=A,35G4]G/H>9F&"HTZ/MJ?5_F4]*\,:AK-H;FU,
M(C#E/G;!R/PKI-%TJ[\(QW^I:@83$(,*$;)+9X%7OA__ ,B\_P#UW;^E0?$.
MZ9--M;8'B67<WT4?_7J:E:I5KN@]KETL-2H898M7YDK_ #>AP-W=S7UW+=7#
M;I96W,?3V^@I+:UGO+A8+:%Y96Z*HR:BY[#)["O6_#.AQ:-IB94&ZE4-,_?/
MI]!79B<1'#PT7H>=@L)+%U'=Z=6<[X2\-75EKLDU_$%-O&"F#D;F]_89KO:*
M*\*O6E6ES2/J<-AH8>') PM5TB6-VU+1R(;]>60?<N!_=8>OO5S1=7AUK3UN
M8P4<';+$>J,.H-:-<;$W]B_$*2!/EM]10,5[;^>?S!_.KA^]@XO=*Z_R,JK]
MA4C-?#)V:\WL_P#,Y_QU_P C/)_UQ2JVE^%M1UBR^UVIA$98K\[$'(_"K/CK
M_D9Y/^N*5U?@+_D65_Z[/_.O3E6E2PL91\CQ:>'AB,?.$]M?S/.]0TV\TB]\
MBZ0Q3 ;E93U'J#7I'@[6I=6TIEN6W7%NVQF_O#L?K7/_ !$EB:_LHE(,J1L6
MQV!(Q5CX<(V-0D_@)1?QP:C$/VV$522U_P""7A(O#X]T8/W?^!<L>#O^1@\0
M_P#7?^IKLLC.,\UYIIG]I7'B#6=/TQ_(>XG+2W/_ #R0$]/<YK7F\ L(S+;:
MS>?:P,AW;@G\.:\<^D.UK-N-"T^ZU>#4Y82;J$81MQQQTR/:LGP?K-W>I=:=
MJ1S?6;;68]6'3GW_ /K56U6XG3XC:5"LTBQ-%EHPQVG[W44@.QI"0.IQ63XC
MUI="TB2ZP&F8[(D/=C_2N=LO"5]K,"WNMZG="64;EBC; 0'I_P#JH [FBN!G
M&I^![V"4W<MYI$K;'$AR4_P/\ZZZ2"YGGCN+:]VP-ABN,AEXZ>G_ ->@#0HH
MHH 9+_JG_P!TUR?P]4#2;ML?,;DY/X"NLE_U3_[IKE/A[_R![K_KY;^0KII_
MP)_+]3BK?[U3])?H:GBV0Q>%K\J<$H%_,@5SVB^,=,TS1K6S:WNB\288K'P3
MW[UT/BV(S>%K]5&2(]WY$&E\+M%<>&K!U53B(*>.XX-:4W!8?WE?7TZ&56-2
M6,]R5GR]K]3(N/'>ESVTL/V:\_>(5YB]1CUJ3P(GG>%I(),[3*Z8QV-=3Y4?
M]Q?RILTT%G;23RLL4,8W,W8"LW6@X<E.-KM=;FL</4515:LT[)K:V_S.&L;V
M]\$RO97UJ\VFM(6CGC'3/^>E==::AINN6K""6*XB88>,]?Q!JQ#-:ZE9K+$R
M3V\HX.,AA7)>(_#,6G0OK&CNUI/!\[(A^4COCT^G2M+PK2M/W9]^E_/L9<M3
M#0O3]^GVZI>3ZG90PQ6\*Q0QK'&HPJJ, 5YCX[_Y&8_]<4_K7H.B7[:IHUK>
M. 'D3+ >O0UY]X[_ .1F/_7%/ZUI@$XXAI[ZF.:RC+"*4=FT=-\/_P#D7G_Z
M[M_2L_XC1G;I\G\.YU_05H?#_P#Y%Y_^N[?TJYXQTUM1\/R^6NZ6 ^:@'4XZ
MC\LTN=0QMWW'[-U,M45O;\M3S'3PIU2S#_=\],_F*]MKPD$\,IP1R#7L/A_5
MX]9TJ.=6'G* LRYY5O\ Z_6M\S@VHSZ'+DE6*<J;W>IJT445Y!]"%<'XEEW>
M/=)2,_/&8\X]V_PKM+Z]@T^SDNKEPD48R3Z^P]Z\\\.^=X@\:-J,JD+&3,1_
M=[*/\^E=N#C92JO9)GF9C-2<*$=VU]R(/'7_ ",\G_7%*Q;?4M0M(O+MKRXB
MCSG;&Q S6UXZ_P"1GD_ZXI72^#+6&\\(O!*@*R22(>.QKT?:JEAH2DK['D>P
ME7QM2$96>IY]#'/J6H1Q&7=/.X7S)6[GU->N:'I$6B:8EI&=S9W2/C[S'J:\
MBNK>73[^6W8E9;>3&?<'@_RKU_1-175='M[L?>=<./1AP?UK',G+DBX_"=&3
M*'M)J2]_^KG.>#O^1A\0_P#7?^IKLZXSP=_R,/B'_KO_ %-=G7CGT1Q5CB'X
MH7Z)P)8,M]< TFK_ /)3-(_ZY?\ Q5+IW^D?$[49$Y6&#:Q]\ 4FK_\ )3-(
M_P"N7_Q5,!?&W[_6M!M'_P!6\^2/7D"NUKBO''^CZMH5ZW^KCGPQ].0:[4$$
M9'(-(#"\90K/X4OPPSL0./8@BIO"\C2^&-.=CDF$#\N*@\9SK;^%+XL<%U"+
M[DD58\,Q-!X9TZ-QAA"#CZ\T :U%%% #9 3$X'4J:YKP1975CI=S'=0/"[7#
M,%<8)&!S73T5I&HU!P[_ *&4J*E4C4[7_$;)&DT3Q2*&1P58'N#7$0V^M^$+
MF6.TM6U#3)&W*J_>3_"NYHJJ59P335T^A%?#JJU).TELT<=)XEUS4$,&FZ'/
M#(W'FS\!?>N@M;"=]#6QU.;[1*\925P,9S6C11.JFK0C85.A*+;J2<KZ>7W(
MX:S?7/"(>S-@^H6 8M$\751_GM1?:AKWB:$V%KI<EG;R<2RS<<5W-%:_6E?G
M<%S=_P#@&/U%\OLU4?)VTV[7W*NFV*:;IUO9QG*PH%R>_J:X7QEI&HWOB S6
MME--'Y2C<BY&>:]$HK.CB)4JGM-V:XG"0KTE2>B1S?@FSN;'0WBNH'AD,S':
MXP<<5TE%%9U)NI-S?4UHTE2IJFNAYIXL\+R:?/)?V49:S<[G51S$?\/Y5S^F
MZG=Z5="YLY=C=&'57'H17M1 (((R#U!KF=4\#Z9?.TMN6M)6Y/EC*G_@/^%>
ME0Q\>7DK?UZGC8K*IJ?M<,[/M_D4;/XB6S(!>V<L;]S%\RG^M27/Q#L$0_9;
M6>5^V_""LN3X=WP;]W?6[+ZLK U9M?AT=P-YJ&5[K"G7\33<<#\5_P Q1GFC
M7+;YZ'/7NIZMXIOXX=I=B?W<$?"K[G_$UZ-X=T./0]-$((>=SNF?U;_ 58TS
M1K'2(3'9P!,_><\LWU-7ZY<3BE./LZ:M%'=@\"Z4G5JOFF_P/.O&.D:E>>(7
MFMK*:6(Q*-Z+D9KI/!EI<67A\0W4+PR>:YVN,'&:Z&BIGBI3I*DUHBZ6!A3K
MNNF[N_XG!>-?#]U<:G%>V-L\WFIME$8S@CH?R_E5GP-#J=@]S9WEG/% _P"\
M1G7@-T(_'^E=I13>+DZ/LFA++X1Q'UB+:?8\\L]*UVTUG5-4L8665)SMAE&%
MN(R3G!]>F*O3>+M;D0P6_ARY2Z(QEP2H/KTKM:*Y#O.<\)Z%/I5O/=7S!K^[
M;?+SG;[9JKJ=A>2_$#3+R.VD:VCBP\H'RJ?FZUUM% &9KVCQ:YI4EG(=K'YH
MWQ]UAT-<S::WX@T&!;'4='FNQ$-L<T.3D=N<<UW-% '"M::SXQOH#J%HUAI<
M+;S$Q^:0UW*J$4*H 4#  [4M% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
